Saturday 17 October 2026
Export UNBX’s income statement to Excel — free account
UNITY Biotechnology, Inc.
UNBX Healthcare Biotechnology
UNITY Biotechnology, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $236,000.00. In the quarter to March 2025, EPS fell 26.5% and free cash flow fell 23.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.06
0.00
0.00%
Follow UNBX
UNITY Biotechnology, Inc. (UNBX) P/E ratio
UNITY Biotechnology, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2025) to 0.0× (October 2025) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2022 | 0.0× | — |
| Dec 2021 | 0.0× | — |
| Dec 2017 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CVKD Cadrenal Therapeutics, Inc. compare | n/m |
| ERNA Ernexa Therapeutics Inc. compare | n/m |
| ADXN Addex Therapeutics Ltd. Sponsored ADR compare | n/m |
| IOBTQ IO Biotech, Inc. compare | n/m |
| PBLA Panbela Therapeutics Inc. compare | n/m |
| PPCB Propanc Biopharma Inc compare | n/m |
| LIPO Lipella Pharmaceuticals Inc. compare | n/m |
| UNBX UNITY Biotechnology, Inc. | n/m |
| CMND Clearmind Medicine Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)